Last reviewed · How we verify
Biological: Solrikitug low dose
Solrikitug is a low-dose biological drug that targets the IL-1β pathway.
Solrikitug is a low-dose biological drug that targets the IL-1β pathway. Used for Treatment of systemic juvenile idiopathic arthritis.
At a glance
| Generic name | Biological: Solrikitug low dose |
|---|---|
| Sponsor | Uniquity One (UNI) |
| Drug class | IL-1β inhibitor |
| Target | IL-1β |
| Modality | Biologic |
| Therapeutic area | Inflammatory diseases |
| Phase | Phase 2 |
Mechanism of action
Solrikitug works by inhibiting the activity of IL-1β, a pro-inflammatory cytokine involved in the pathogenesis of various inflammatory diseases. By blocking IL-1β, solrikitug aims to reduce inflammation and alleviate symptoms associated with these conditions.
Approved indications
- Treatment of systemic juvenile idiopathic arthritis
Common side effects
- Injection site reactions
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biological: Solrikitug low dose CI brief — competitive landscape report
- Biological: Solrikitug low dose updates RSS · CI watch RSS
- Uniquity One (UNI) portfolio CI